Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 3 4Phase 1 2

Status

Completed 4Withdrawn 1Unknown 1Active not recruiting 1

Sponsor Class

NIH 2OTHER 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other neoplasm 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Urinary Bladder Neoplasms 1Precancerous Conditions 1Carcinoma, Basal Cell 1Adenomatous Polyposis Coli 1

Interventions

Cyclophosphamide 299Cisplatin 298Paclitaxel 257Radiotherapy 255Fluorouracil 234Carboplatin 234Docetaxel 230Doxorubicin 216Dexamethasone 166Gemcitabine 156Vincristine 147Etoposide 136Leucovorin 133Capecitabine 129Bevacizumab 129Prednisone 125Rituximab 118Methotrexate 118Cytarabine 110Filgrastim 99Trastuzumab 97Oxaliplatin 96pembrolizumab 83Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Daunorubicin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Completed × Eflornithine × Clear all
NCT01483144 2021-06-08

Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

Cancer Prevention Pharmaceuticals, Inc.

Phase 3 Completed
171 enrolled 13 charts
Gastrointestinal

Adenomatous Polyposis Coli

NCT00005884 2019-12-13

Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer

University of Wisconsin, Madison

Phase 3 Completed
Dermatologic

Carcinoma, Basal Cell

NCT00118365 2015-01-22

Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps

National Cancer Institute (NCI)

Phase 3 Completed
375 enrolled 27 charts
Other neoplasm

Precancerous Conditions

NCT00003814 2013-12-18

Eflornithine in Treating Patients With Bladder Cancer

National Cancer Institute (NCI)

Phase 3 Completed
450 enrolled
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡